Research
Find a program, inspect its clinical evidence, and follow the next regulatory event.
10 programs10 companies20 publications
10 drugs shown
| Drug / program | Sponsor | Indication | Sponsor target | Published evidence |
|---|---|---|---|---|
| Lonvo-z Gene editing lonvoguran ziclumeran · lonvo-z · NTLA-2002 | NTLAIntellia Therapeutics | hereditary angioedema | Mar 10, 2027Date-only guidance | 2 exact-program2 total publications · 1 notesReview evidence |
| Tinlarebant Small molecule tinlarebant · LBS-008 | BLTEBelite Bio | Stargardt disease type 1 | Feb 12, 2027Date-only guidance | 0 exact-program2 total publications · 2 notesReview evidence |
| Z-rostudirsen ASO / siRNA zeleciment rostudirsen · z-rostudirsen · DYNE-251 | DYNDyne Therapeutics | Duchenne muscular dystrophy amenable to exon 51 skipping | Jan 21, 2027Date-only guidance | 0 exact-program1 total publications · 1 notesReview evidence |
| AXS-12 Small molecule AXS-12 · reboxetine | AXSMAxsome Therapeutics | cataplexy in narcolepsy | May 1, 2027Date-only guidance | 0 exact-program2 total publications · 3 notesReview evidence |
| Encaleret Small molecule encaleret · CLTX-305 | BBIOBridgeBio Pharma | autosomal dominant hypocalcemia type 1 (ADH1) | May 8, 2027Date-only guidance | 1 exact-program2 total publications · 5 notesReview evidence |
| Zanzalintinib + atezolizumab Small molecule zanzalintinib · XL092 | EXELExelixis | metastatic colorectal cancer | Mar 3, 2027Date-only guidance | 2 exact-program3 total publications · 5 notesReview evidence |
| Deucrictibant Small molecule deucrictibant | PHVSPharvaris | on-demand treatment of hereditary angioedema attacks | Apr 23, 2027Date-only guidance | 2 exact-program2 total publications · 1 notesReview evidence |
| Ozekibart Antibody ozekibart · INBRX-109 | INBXInhibrx Biosciences | unresectable or metastatic conventional chondrosarcoma | Apr 14, 2027Date-only guidance | 1 exact-program1 total publications · 2 notesReview evidence |
| Oxylanthanum carbonate Other modality oxylanthanum carbonate · OLC | UNCYUnicycive Therapeutics | hyperphosphatemia in chronic kidney disease patients on dialysis | Mar 25, 2027Date-only guidance | 1 exact-program2 total publications · 2 notesReview evidence |
| Oral lenacapavir Small molecule lenacapavir | GILDGilead Sciences | HIV pre-exposure prophylaxis | Feb 2, 2027Date-only guidance | 0 exact-program3 total publications · 3 notesReview evidence |
How evidence coverage is classified
- Exact program
- Publications linked to the named program and indication. Study design, endpoint and population still need to be read.
- Related evidence
- The same compound or adjacent science, kept separate from direct evidence for this application.
- Context notes
- Corrections, retractions and formulation differences remain attached to their records. Counts are coverage, not approval probabilities.
Follow a program through its studies, publications and next catalyst.